Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
08 Ottobre 2024 - 12:15PM
Counterpart Health, Inc. (“Counterpart”), a leading AI-powered
physician enablement platform, today announced the appointment of
David Tsay M.D., Ph.D as Chief Medical Officer
(CMO). Dr. Tsay will play a key role in advancing Counterpart’s
clinical strategy and product roadmap for Counterpart Assistant,
the company’s proprietary AI-powered physician enablement software
platform that empowers providers to deliver high-quality,
cost-effective care. Counterpart is a subsidiary of Clover Health
Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).
David Tsay is a distinguished physician executive with deep
expertise and over two decades of experience in health technology,
product development, and clinical innovation. Prior to Counterpart,
Dr. Tsay served in clinical leadership roles in the technology
industry, most recently as Chief Medical Officer at Cue Health
where he led regulatory, clinical, and medical affairs. Before Cue
Health, Dr. Tsay led the clinical team for digital health medical
device products at Apple. Prior to Apple, Dr. Tsay served as
Associate Chief Transformation Officer at New York-Presbyterian
(NYP), one of the nation's most comprehensive academic healthcare
delivery systems, leading digital transformation initiatives for
NYP in artificial intelligence, automation, and digital web/mobile
technologies.
Dr. Tsay received his BA in Computer Science and Physics from
Columbia University College, M.D., Ph.D degrees from Columbia
University College of Physicians and Surgeons, and is board
certified in internal medicine and cardiology.
"Counterpart Health is built on groundbreaking technology that
empowers physicians to excel in value-based care, particularly in
the management of chronic diseases," said Conrad Wai, CEO of
Counterpart Health. "Dr. Tsay’s world-class expertise in clinical
innovation and health technology makes him a valuable addition to
our team. I’m confident that his leadership will be instrumental as
we accelerate our expansion into more value-based healthcare
networks and systems nationwide."
"I’ve had the privilege of contributing to world-class
institutions like Apple and NewYork-Presbyterian, which operate at
the critical crossroads of healthcare and technology. Counterpart
attracted me because it offers one of the most compelling solutions
I’ve encountered," Tsay remarked. "With an increasing number of
providers looking to deliver value-based care, Counterpart
Assistant provides an innovative technology designed specifically
for this purpose. I look forward to working alongside this skilled
team in its mission to help improve providers’ and patients’
lives."
For companies interested in learning more about how Counterpart
can reduce the total cost of care in value-based care models
through advanced chronic disease management, visit
www.counterparthealth.com.
About Counterpart HealthCounterpart Health, a subsidiary of
Clover Health Investments, Corp., or Clover Health, is a leading
AI-powered physician enablement platform. Counterpart Health’s
flagship software platform, Counterpart Assistant, was incubated by
Clover Health as Clover Assistant and has helped improve plan
performance and clinical outcomes for Medicare members through
proprietary AI technology. Counterpart Health extends the benefits
of the data-driven technology platform outside of Clover Health’s
Medicare Advantage plan to a wider audience, to enable enhanced
patient outcomes and reduced healthcare costs nationwide. Clover
Health has published data demonstrating the technology’s impact on
Medication Adherence, as well as the earlier identification and
management of Diabetes and Chronic Kidney Disease.
Press Contact:Andrew
Still-Baxterpress@cloverhealth.com
Investor Relations Contact:Ryan
Schmidtinvestors@cloverhealth.com
Grafico Azioni Clover Health Investments (NASDAQ:CLOV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Clover Health Investments (NASDAQ:CLOV)
Storico
Da Dic 2023 a Dic 2024